Report Descriptions:

The Global Shingles Vaccine Market was estimated at USD 5.42 billion in 2026 and is projected to reach USD 25.06 billion by 2035, reflecting a robust CAGR of 16.55% over the forecast period from 2026 to 2035. The Shingles Vaccine market report offers a comprehensive and nuanced view of the industry, moving beyond conventional analysis. It provides a thorough examination of the markets dynamics, encompassing a detailed exploration of the factors propelling growth, such as evolving economic conditions, advancements in technology, shifts in regulatory policies, and changes in consumer behavior. Furthermore, the report discusses the projected Compound Annual Growth Rate (CAGR), providing stakeholders with a clear understanding of the market's expected growth trajectory and offering data-driven insights into future market dynamics.

The Shingles Vaccine market under analysis is characterized by dynamic growth and evolving trends that are reshaping the competitive landscape. With 2025 serving as the base year for this Shingles Vaccine market study, recent data highlights a significant expansion driven by technological advancements, rising consumer demand, and a growing focus on innovation. Companies are refining their go-to-market (GTM) strategies to effectively capture these emerging opportunities and respond to the rapidly changing market dynamics.

Key trends influencing the Shingles Vaccine market include the rapid adoption of digital technologies, the integration of sustainable practices, and the increasing importance of customer experience. These trends are not only driving growth but also creating new challenges for industry participants, who must adapt their GTM strategies to navigate regulatory changes, supply chain disruptions, and fluctuating economic conditions. Despite these challenges, the Shingles Vaccine market is poised for sustained growth, with emerging markets playing a critical role in the expansion of the industry.

Looking ahead, the Shingles Vaccine market is forecasted to continue its upward momentum through 2035, supported by ongoing investments in research and development, strategic partnerships, and mergers and acquisitions. Companies that can effectively tailor their GTM strategies to the evolving market landscape, innovate, and meet shifting consumer demands are likely to achieve sustained success. Shingles Vaccine market report provides a comprehensive analysis of the current market environment and offers valuable insights into the key drivers, challenges, and opportunities that will shape the industry's future over the next decade. This report offers a comprehensive analysis of market dynamics across various segments, regions, and countries, incorporating both qualitative and quantitative data. It covers the period from 2017 to 2035, providing a detailed examination of historical performance, current market conditions, and future projections.

Historical Analysis (2017-2024): The report presents a thorough review of market trends, performance metrics, and growth trajectories for the years 2017 through 2024. This historical perspective is crucial for understanding past market behavior and identifying patterns that influence current and future market dynamics.

Forecast and Projections (2026-2035) : Building on historical data, the report provides forward-looking insights, including market forecasts and growth projections from 2026 to 2035. It details anticipated market trends, emerging opportunities, and potential challenges across different segments, regions, and countries.

Compound Annual Growth Rate (CAGR): The report includes a precise calculation of the compound annual growth rate (CAGR) for the forecast period of 2026 to 2035. This metric will be instrumental in assessing the expected growth trajectory and the overall market potential during the forecast period.

Shingles Vaccine Market

Shingles Vaccine Market

The Shingles Vaccine Market refers to the global and regional landscape including vaccines developed to prevent herpes zoster also known as shingles, especially in older adults or immunocompromised individuals. It includes recombinant subunit vaccines and live attenuated vaccines like Zostavax, and emerging vaccines such as mRNA based shingles vaccines.

It provides to the market stakeholders, which include vaccinespharmaceutical industries, health systems, vaccination programs and public health agencies. Growth isfuelled by strong adult immunisation programs, increased awareness of the risk of shingles, the integration of the vaccines into national immunisation programs, eased regulatory hurdles and government sponsored vaccination programs.

• Shingles is on therise due to the growing aging population of the world. As people get older, immune system declines and older adults are more immunocompromised when it comes to the herpeszoster and its complications, such as postherpetic neuralgia. This demographic shift is a big reason why so many people are opting for vaccines.
• Health authorities around the world, including the U.S. CDCs Advisory Committee on Immunisation Practices (ACIP), have rolled out official recommendations for shingles vaccinations for adults aged 50 and up. These guidelines not only strengthen public health policies but also help boost market growth by creating a steady demand.
• There's a noticeable trend in clinical practice leaning towards recombinant subunit vaccines like Shingrix instead of live attenuated vaccines. This shift is largely due to better immunogenicity, long-lasting protection, and a safer profile for those with weakened immune systems. As a result, this change is boosting the market potential.
• Public health education campaigns, along with a growing awareness among healthcare providers, have helped in recognising the risks tied to shingles and the advantages of getting vaccinated early. A physician's recommendation plays a vital role in ensuring that patients follow through, which in turn has a positive impact on market growth.
• Medicare Part D reimbursement systems, along with private insurance and public health programs in various countries, have an important role in enabling shingles vaccines for olderpersons. Such financial inducements will reduce cost barriers to patients and help generate a more universal applicationof prophylactic immunisation strategies.

• The shingles vaccine is costlier than most other adult vaccines, especially the recombinant types likeShingrix. For people living in low- and middle-income countries (LMICs), where people pay out of pocket for healthcare, this high cost can be a deterrent to gettingvaccinated. This is compounded by scarce public resources and the absenceof state vaccination programs, which further complicates the situation.
• Even though clinical guidelines suggest that adults aged 50 and older should get vaccinated against shingles, many people still aren't aware of it in various areas. Some patients have misconceptions about the vaccine's safety, others simply don't know much about herpes zoster, and many doctors aren't reaching out regularly to discuss it.
• Recombinant zoster vaccines must be stored at fixed cold temperatures and require more than one dose in some cases, which may pose issues for healthcare providers in rural orresource-poor settings. Such hurdles could result in delays in getting the vaccinesout, eroding effectiveness, while also complicating efforts to ensure that people living in isolated or underserved communities get vaccinated.

North America: As a result of strong public health initiatives, robust insurance infrastructure, and high consumer awareness, North America stands asthe leading region for the shingles vaccine. At the US level, CDC recommendations for adult immunisation and Medicare Part D coverage have been critical in increasing vaccination coverage. Canada offers broad access via government-funded programs through provincial health systems. Continued education campaigns bygroups such as the National Foundation for Infectious Diseases (NFID), with CDC support, help healthcare professionals recommend and administer shingles vaccines.

Europe: The Europeanmarket is progressing with formal adult immunisation schedules in countries such as the UK, Germany, and France. Government programmes and EU health directives are aiding better access andcoverage. Advocacy by organisations such as the European Centre for Disease Prevention and Control (ECDC)and national immunisation task forces is essential for raising awareness among both healthcare professionals and the public.

Asia Pacific: Demand is increasing with improved awareness and aging populations in countries like Japan, Australia, and South Korea. Few national immunisation organisations currently recommend shingles vaccines for olderpeople. Public health campaigns and WHO partnerships are working to improve vaccine educational programs. Specialised clinics in major cities are beginning to include shingles vaccines in regular adult schedules.

Latin America: Demand is growing, driven by national immunisation programs and employer-provided health plans. The Pan American Health Organization(PAHO) and local groups are raising awareness. Somenational health authorities are making shingles vaccines available to high-risk groups such as seniors.

Middle East & Africa: Uptake is beginning in the UAE, Saudi Arabia, South Africa, and Morocco. Health ministries are exploring vaccine inclusion in adult immunisation plans based on WHO recommendations. Regional groups such as MENACTRIMS and public-private partnerships are starting education programs for healthcare providers.

• United States: ACIP recommends two Shingrix doses for adults aged 50+. Medicare Part D and private insurance plans cover the vaccine in full. Pharmacies and clinics have simplified access. Initiatives like the Inflation Reduction Act have made it more affordable, with provider recommendations driving uptake.
• Germany: STIKO includes shingles vaccination in its routine program for adults. Vaccines are easily accessible via public health services and covered by statutory health insurance. RKI campaigns target older adults and immunocompromised individuals, integrating shingles vaccination into preventive care.
• Japan: The MHLW has added shingles vaccines to the national immunisation program starting FY 2025, targeting adults aged 65+. Shingrix has been approved since 2018 for those aged 50+, with recent initiatives focusing on integrating shingles vaccination into broader chronic disease prevention strategies.

The Shingles Vaccine Market is competitive, driven by innovations in vaccine formulation and delivery, as well as strategic partnerships. Major players like GlaxoSmithKline (GSK) and Merck dominate with products such as Shingrix and Zostavax. GSKs recombinant subunit vaccine Shingrix leads the market due to its high efficacy and suitability for immunocompromised individuals. R&D in adjuvant technologies and stable formulations is key to maintaining a competitive edge.

Regulatory approvals, NIP inclusion, and public health body support (WHO, EMA, U.S. FDA) influence market dynamics. Pricing and reimbursement strategies differentiate companies, as do robust distribution networks and manufacturing capabilities with strong cold-chain logistics. Patient education and targeted campaigns addressing vaccine hesitancy among elderly and vulnerable groups further boost market share.

Key players: GlaxoSmithKline plc (GSK), Merck & Co., Inc., Sanofi Pasteur, Pfizer Inc., Johnson & Johnson, Emergent BioSolutions Inc., Mitsubishi Tanabe Pharma Corporation, Bavarian Nordic, Moderna Inc., Novavax Inc., AstraZeneca, Valneva SE, Sinovac Biotech Ltd., Bharat Biotech, Serum Institute of India.

• In March 2025, the U.S. FDA approved Shingrix for adults aged 18+ who are immunocompromised or immunosuppressed, including those with HIV or undergoing hematologic treatments.
• In January 2025, the FDA approved new Shingrix labelling with Phase III Zoster-049 data showing over a decade of protection for adults aged 50+.
• In January 2025, the European Medicines Agency began reviewing a new pre-filled syringe design for Shingrix to simplify administration in clinical settings.

Study Period for the Shingles Vaccine Market:

Shingles Vaccine Market

Report Highlights:

Our team of experienced researchers has meticulously gathered and analyzed data to deliver a thorough examination of market dynamics, competitive landscape, and emerging technologies. With a focus on delivering actionable intelligence, this report aims to empower decision-makers with the information needed to make informed choices and stay ahead of the competition. Whether you are a seasoned industry player or a new entrant, our market research report serves as a strategic tool to navigate the complexities of the market, aiding in successful business planning and growth strategies.

Key Chapters of our Shingles Vaccine Market Report includes:

Market Dynamics, Variables, and Industry Analysis:

This chapter of our Shingles Vaccine market report provides an in-depth examination of the factors shaping the industry landscape. This section typically encompasses several key elements to offer a comprehensive understanding of the industry landscape such as market drivers & restraints analysis, market opportunities & trend analysis, market size & growth analysis, competitive analysis, SWOT analysis, business environment tools such as Porter's five forces & PESTEL analysis, Ansoff Matrix analysis, penetration & growth prospect analysis, regulatory framework & reimbursement scenario analysis, impact of macro & micro economic factors analysis such as Covid-19 impact, GDP growth, market inflation, U.S.- China trade war, Russia-Ukraine war impact, and supply chain analysis.

Segment Analysis & Forecast to 2035:

The segment analysis chapter of Shingles Vaccine market report is a critical section that delves into a detailed examination of the market's various segments. Segmentation involves dividing the market into distinct categories based on certain criteria to better understand and address the diverse needs of consumers. This chapter typically follows the introduction and provides a more granular view of the market, offering valuable insights for businesses and stakeholders. The components of the chapter lude segment definitions to understand the inclusions and exclusions of the study, assumptions, market size estimates and growth trend analysis of each segment, qualitative analysis of the segment, technological advancements, market penetration rate, market adoption rate, market share examination by each segment, segment growth drivers and restraint barriers, consumer behaviour and challenge analysis.

Regional Market Analysis & Forecast to 2035:

The chapter in Shingles Vaccine market research report is a pivotal section that examines and predicts the market dynamics and trends specific to different geographical regions. This chapter is crucial for businesses and stakeholders seeking a comprehensive understanding of how the market behaves across various locations, enabling them to tailor strategies and make informed decisions based on regional variations. The regional analysis chapter of our Shingles Vaccine market report is classified into regions & country-level. The chapter consists of North America (U.S., Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Sweden, Denmark, Norway, Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Colombia, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East & Africa).

Shingles Vaccine Market

Competitive Analysis & Company Profiles:

This section of a Shingles Vaccine market report is a crucial segment that provides a comprehensive overview of the competitive landscape within the market. This section is vital for businesses, investors, and stakeholders seeking insights into key players, their market positioning, strengths, weaknesses, strategies, and potential impacts on the overall market dynamics. The chapter includes research methodology used to analyse the market competition, list of key players operating in the market, detailed company profile section which includes company overview, business verticals, financial performance, product/services benchmarking, geographical presence, and strategic initiatives.

• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc.
• Pfizer Inc.
• Johnson & Johnson
• Sanofi Pasteur
• Emergent BioSolutions Inc.
• Mitsubishi Tanabe Pharma Corporation
• Bavarian Nordic
• Moderna Inc.
• Novavax Inc.
• AstraZeneca
• Valneva SE
• Sinovac Biotech Ltd.
• Bharat Biotech
• Serum Institute of India

Shingles Vaccine Market

Report Scope:

Based on Market Type, the Shingles Vaccine market is segmented into:

• Gross Written Premiums (GWP)
• New Business Premiums (NBP)

Based on Insurance Sector, the Shingles Vaccine market is segmented into:

• Public [By Policy Type (Corporate Policy
• Retail Policy)]
• By Distribution Channel (Individual Agents
• Corporate Agents
• Brokers
• Direct Sale
• Others)
• Private [By Policy Type (Corporate Policy
• Retail Policy)]}
• By Distribution Channel (Individual Agents
• Corporate Agents
• Brokers
• Direct Sale
• Others)

Based on Policy Type, the Shingles Vaccine market is segmented into:

• Corporate Policy
• Retail Policy

Based on Distribution Channel, the Shingles Vaccine market is segmented into:

• Individual Agents
• Corporate Agents
• Brokers
• Direct Sale
• Others
• Traditional Distribution Channels
• Digital/Online Distribution Channels

Key Reasons to Acquire the Shingles Vaccine Market Research Report:

• This report offers a comprehensive analysis of the Shingles Vaccine market from 2017 to 2035, including market segments, current trends, estimations, and dynamics
• It also provides information on key drivers, restraints, and opportunities
• Porter's five forces analysis is used to assess the potency of buyers and suppliers, helping stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network
• The report includes an in-depth analysis of the Shingles Vaccine market segmentation to identify prevailing market opportunities
• Major countries in each region are mapped according to their revenue contribution to the global market
• Market player positioning is also analyzed to facilitate benchmarking and provide a clear understanding of the present position of the market players
• The report includes an analysis of the regional and global Shingles Vaccine market trends, key players, market segments, application areas, and market growth strategies

Shingles Vaccine Market

Available Customizations:

With the given market data, Quintile Reports offers customizations according to the company's specific needs. The following customization options are available for the report:

• You may ask for a global, regional, or country-specific report.
• You may ask if there are any particular types, applications, or products on which you would like to focus.
• You may ask for specific competitors/players to be profiled.

Shingles Vaccine Market Report

Statistics for the 2025 Shingles Vaccine market share, size, and revenue growth rate were created by Quintile Report™. Shingles Vaccine analysis includes a market forecast outlook for 2035 and a historical overview. Get a free PDF sample of this market analysis, please get in touch with our principal analyst at sales@quintilereports.com